Activists ready to fight for Ariad CEO’s ouster: CNBC

Carly Helfand Industry-watchers knew a shake-up could be in Ariad Pharmaceuticals' future when Alex Denner, founder of activist hedge fund Sarissa Capital and protégé ...

Incoming Takeda chief ready to jump on the M&A train with reorg in place

Carly Helfand Step one for incoming Takeda CEO Christophe Weber: Reorganize. Step two? Scout deals, he said Wednesday. FiercePharma News

Actavis ready to thwart Valeant with $60B-plus Allergan buyout: Bloomberg

Carly Helfand Heads up, Valeant. Actavis is reportedly in talks to snatch up Allergan–and word is it could happen quickly. FiercePharma News

Express Scripts ready to favor AbbVie hep C prospect–provided it undercuts Gilead

Carly Helfand Express Scripts–which has made its feelings well known when it comes to the high cost of Gilead's next-gen hepatitis C drugs–says it may quickly change ...

PhRMA jumps into Integrilin off-label case, free-speech arguments at the ready

Tracy Staton Since a U.S. circuit court decided the First Amendment protected a pharma sales rep from off-label marketing charges, the free-speech arguments have multiplied in cases ...

Prefer a Swiss tax rate? Basilea chief says he’s ready to parley

John Carroll Basilea CEO Ronald Scott offered that the next best step for the biotech may be to just sell the Basel-based company to a U.S.-based biopharma company interested in a quick ...

U.K. pols ready for Pfizer’s return, AZ cozies up to EU academia, Israeli biotech upsizes IPO

Nick Paul Taylor In this week's EuroBiotech Report, no politicians are rushing to Shire's rescue as it attempts to fend off AbbVie, but lawmakers in the United Kingdom are readying ...

Reckitt is indeed after Merck’s consumer unit, and it’s ready for a close race

Carly Helfand As Reuters reported this weekend, Reckitt and Germany's Bayer have emerged as front-runners for the unit, which could go for $ 13.5 billion–or higher, ...

CURx picks up a Gilead cystic fibrosis drug ready for Phase III

Damian Garde San Diego startup CURx has paid an undisclosed sum to license an antiobitic developed by Gilead, planning to launch a Phase III trial on the drug to treat lung infections ...

Google visionaries ready to invest a fortune in revolutionizing aging process

John Carroll When the founders of global search leviathan Google stepped up recently to provide a few tidbits of information about their new biotech startup Calico, industry execs eagerly ...

GSK, Sanofi, AstraZeneca ready to roll out premium-priced flu vaccines

Tracy Staton Will a new generation of flu shots pay off big for vaccine makers? We'll soon find out. As Reuters reports, several top drug companies are rolling out vaccines that ...

Vivus hands control to rebel investors, with new CEO ready to step in

Alok Saboo Under the deal, which has to be approved by shareholders, the board of directors will expand to 11 members from 9. Vivus will retain four board seats and FMC's nominees ...
Page 1 of 212
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS